BioCentury | Nov 23, 2020
Deals

Cytokinetics evaluating path forward for heart disease treatment after Amgen ends partnership

Cytokinetics is assessing whether to commercialize omecamtiv mecarbil on its own or to seek a new partner after Amgen returned the heart failure treatment’s rights, ending a 2006 deal. President and CEO Robert Blum told a...
BioCentury | Nov 13, 2020
Product Development

Cytokinetics sees path to market for omecamtiv mecarbil in more severe heart failure patients

Updated data from the Phase III GALACTIC-HF study of omecamtiv mecarbil show it may be particularly useful in a more severe subgroup of heart failure patients. The latest readout from Cytokinetics...
BioCentury | Oct 23, 2020
Product Development

Fresh $20M allows Azura to move lead candidate into pivotal testing for major cause of dry eye

With a new $20 million financing that doubles what the company has raised to date, Israel’s Azura will be able to advance its lead program into a registrational study to address a major cause of dry...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Oct 8, 2020
Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

Pivotal heart failure data 14 years in the making tripped up Cytokinetics and Amgen Thursday, leaving the former company looking ahead to 1H21 to complete enrollment for another Phase III study of omecamtiv mecarbil. Its next hope is the...
BioCentury | Oct 5, 2020
Deals

Bristol Myers adds CV therapy through $13.1B MyoKardia takeout

BMS is looking to diversify beyond its heavy reliance on its cancer portfolio through a $13.1 billion takeout of cardiovascular company MyoKardia. For MyoKardia Inc. (NASDAQ:MYOK), the $225 per share acquisition price is a 61%...
BioCentury | Sep 8, 2020
Product Development

Biopharmas must address the reality of racial disparities in health outcomes exposed by COVID-19

This is the second article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

Led by Bing Li and Debra Yu, Perceptive’s LianBio has launched with the goal of speeding the entrance of new medicines into Asian markets, leading with a registration-ready cardiomyopathy candidate from MyoKardia and a Phase...
BioCentury | Jul 31, 2020
Product Development

Can the vogue of decentralized trials continue beyond the pandemic?

Decentralizing clinical trials has become a must-do rather than nice-to-have during the pandemic, with hospital shutdowns and restricted access disrupting company programs and putting enrolled patients at risk. But a range of logistical challenges need...
BioCentury | Jul 25, 2020
Product Development

Real-world data’s power to increase racial diversity in clinical research

Real-world data has come into focus as one of the most important resources for accelerating drug development and defining the natural history of the disease during the pandemic, but it also represents one of the...
Items per page:
1 - 10 of 321